(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Explainer-What has happened to the damaged spacecraft at China's space station?- Telescope in Chile captures stunning new picture of a cosmic butterfly
- 7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
- Japan deploys the military to counter a surge in bear attacks
- German finance minister sees advantages of smartphones in schools
- Tech for Learning: Online Courses and Instructive Devices
- Pleasant Cycle Courses All over the Planet
- The most effective method to Pick The Right Speakers
- Alice Wong, founder of the Disability Visibility Project, dies at 51
